Chikungunya virus (CHIKV) is a mosquito-borne alphavirus endemic in Africa and Asia that causes a debilitating disease in over 2 million people every year in explosive outbreaks. There are currently no vaccines or therapeutics available for this emerging virus. IBT Bioservices has established a lethal model for this disease based on the model published by Partidos et al, Probing the attenuation and protective efficacy of a candidate Chikungunya virus vaccine in mice with compromised interferon (IFN) signaling, (Vaccine, 2011: 3067-73).
The model utilizes AG129 mice deficient in IFNa/B and IFNg signaling as well as an attenuated strain of CHIKV (181/25). This model is ideal for testing antiviral drugs and CHIKV vaccine candidates and has the following advantages: